Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

This results in an increase in tumor cell PSA expression followed by induction of apoptosis, which releases PSA into circulation. As tumor cell death occurs, the PSA is expected to decline or stabilize.

"Based on the encouraging responses and the tolerability profile we have seen in these end-stage patients, we are dose-escalating to 200 mg per day," commented Dr. Montgomery. "As we track time to progression through further treatment cycles, we expect that PSA levels will remain stable or continue to decline, consistent with the unique mechanism of this drug, which is distinct from other compounds in later-stage development for CRPC."

Howard Scher, M.D., Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan-Kettering and Principal Investigator of the PCCTC, added: "These data provide initial evidence of activity in late-stage prostate cancer. The next step will be to expand the subject eligibility criteria to include earlier-stage, chemotherapy-naive patients in a controlled Phase II trial."

APOPTONE Clinical Trial Design

The study is an open-label study with the primary objective of assessing safety, tolerance, PK and activity of Apoptone in men with CRPC and an ECOG PS of <2 who failed at least one taxane-containing chemotherapy regimen and either radiographically or biochemically progressed. Patient cohorts are defined by oral twice-daily doses of 10 mg, 20 mg, 30 mg, 50 mg, 100 mg or higher (MTD has not yet been reached). Subjects are treated on 28-day cycles until toxicity or disease progression; CT and bone scans are obtained every two cycles to assess progression.

About Prostate Cancer

Over one million men in the United States have prostate cancer; approximately 90,000 of these patients have late-stage prostate cancer, resulting in approximately 28,000 deaths each year. There are currently no approved treat
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ ... a technology-focused supplier of crop seeds in China ... for its fiscal year 2014 ended September 30, 2014, before ... The Company will host a teleconference on January 8, 2015, ... time to discuss the results. To participate in ...
(Date:12/13/2014)... Clarassance, a privately held clinical-stage biotechnology company based ... Therapeutics , Inc. The new name is derived from ... in the lungs similar to branches on a tree), ... therapeutics for the treatment of respiratory diseases. , ... to mark the company's escalation into the clinical phase ...
(Date:12/13/2014)... 13, 2014 According to population studies: ... between now and 2030." If a population explosion like ... most populous state in the country. , To that ... the Future of North Carolina Forum on December 16th ... have the necessary infrastructure in place? Enough clean water? ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex ... the discovery and development of therapeutic monoclonal ... today announced publication of a manuscript entitled ... inhibits remyelination in neurodegenerative disease" in the ... of Disease*.  The publication highlights an important ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... ... NEW YORK, Nov. 16 Sharon L. Allen, Chairman of the,Board, ... of,the American Friends of the Phelophepa Train (AFPT). "It,s an honor, ... Archbishop Desmond Tutu and Ms. Leah Tutu in bringing,awareness to the healthcare ...
... led in the discovery of genes that confer risk of, ... ... AM EST, REYKJAVIK, Iceland, Nov. 16 deCODE genetics,(Nasdaq: DCGN ... to get a detailed look at their own,genome. Through your subscription ...
... This release is available in German . ... but simple methods for the production of tiny particles ... special regular patterns in two or three dimensions and ... objects have countless applications in modern technology, from diagnostic ...
Cached Biology Technology:Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train 2deCODE Launches deCODEme(TM) 2deCODE Launches deCODEme(TM) 3deCODE Launches deCODEme(TM) 4Two-faced miniatures 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... . . People with tomorrow,s prosthetic ... cold and touch through a series of developments by ... different ORNL research groups, Ilia Ivanov and Dave Geohegan ... John Simpson of the superhydrophobic materials group, are combining ...
... -- If projected increases in the use of corn ... could be considerable, and water supply problems at the ... new report from the National Research Council. The ... identified opportunities for new agricultural techniques and technologies to ...
... found in the environment may be interacting with the ... easier because of a new field of science called ... National Academies of Sciences (NAS) recognizes the importance of ... the integration of toxicogenomics into regulatory decision making. ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, October 2007 2Increase in ethanol production from corn could significantly impact 2Increase in ethanol production from corn could significantly impact 3NAS report offers new tools to assess health risks from chemicals 2